Ironwood Pharmaceuticals Details Strategy To Establish Leading Gastrointestinal Therapeutics Company
12/12/2013 8:22:32 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will detail its strategy to establish a leading gastrointestinal (GI) therapeutics company during its Investor Day today in New York City. This strategy leverages Ironwood’s strong development and commercial capabilities in addressing GI disorders as well as its pharmacologic expertise in guanylate cyclase (GC) pathways, all of which is based on Ironwood’s pioneering work bringing forward LINZESS, the first FDA-approved product in a new class of GI medicines called GC-C agonists.
Help employers find you! Check out all the jobs and post your resume.
comments powered by